CENTUSSIN DHC Liquid
NDC 23359-018-16
Rx Only

CV
DESCRIPTION:
Each 5 mL (one teaspoonful) for oral administration contains:
Dihydrocodeine Bitartrate*........................ 3 mg
*(WARNING- May be habit forming)
Brompheniramine Maleate........................ 4 mg
Phenylephrine Hydrochloride................... 7.5 mg

CENTUSSIN DHC Liquid also contains: Glycerin, Propylene Glycol, Sorbitol, Citric Acid, Sodium Citrate,
Sodium Saccharin, Grape Flavor, Purified Water.

Dihydrocodeine Bitartrate is an antitussive with the chemical name (Morphinan-6-ol,4,5-epoxy-3-methoxy-
17-methyl-, (5α, 6α)-2,3-dihydroxybutanedioate (1:1) (salt). It has the following structural formula:

Brompheniramine Maleate is an antihistamine having the chemical name, 2-Pyridinepropanamine,
γ-(4-bromophenyl)-N, N-dimethyl-, (±)-,(Z)-2-butenedioate (1:1). With the following structure:

Phenylephrine hydrochloride is an orally effective nasal decongestant. Chemically it is (-)-m-Hydroxy-α-
[(methylamino)methyl]benzyl alcohol hydrochloride. Its chemical structure is as follows:

CLINICAL PHARMACOLOGY
Dihydrocodeine is a semi-synthetic narcotic analgesic related to codeine, with multiple actions
qualitatively similar to those of codeine; the most prominent of these involve the central nervous
system and organs with smooth muscle components. Brompheniramine maleate is an alkylamine
type antihistamine. This group of antihistamines is among the most active histamine antagonists
and is generally effective in relatively low doses. The drugs are not so prone to produce
drowsiness and are among the most suitable agents for daytime use, but a significant proportion
of patients do experience this effect. Phenylephrine HCl is a sympathomimetic, which acts
predominately on alpha-receptors and has little action on beta-receptors. It therefore functions
as an oral nasal decongestant with minimal CNS stimulation.

INDICATIONS AND USAGE
CENTUSSIN DHC Liquid is indicated to control cough and provide for temporary relief from
congestion associated with the upper respiratory tract.

CONTRAINDICATIONS
This combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine,
or any of the active and inactive components listed above, or in any situation where opioids are
contraindicated including significant respiratory depression (in unmonitored settings or in the absence
of resuscitation equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus.
Antihistamines and sympathomimetics are contraindicated in patients receiving antihypertensive or
antidepressant drugs containing monoamine oxidase (MAO) inhibitors. Antihistamines should not be
used to treat lower respiratory tract symptoms or be given to premature or newborn infants.
Sympathomimetic agents are contraindicated in patients with severe hypertension, severe coronary
artery disease, patients with narrow angle glaucoma, bronchial asthma, urinary retention, peptic ulcer,
and during an asthma attack. This product is contraindicated in women who are pregnant.

WARNINGS
General: Considerable caution should be exercised in patients with hypertension, diabetes mellitus,
ischemic heart diseas